Antares Pharma (ATRS) Receives Daily News Sentiment Score of 0.13
News stories about Antares Pharma (NASDAQ:ATRS) have been trending somewhat positive this week, according to Accern Sentiment. The research group identifies positive and negative media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Antares Pharma earned a news sentiment score of 0.13 on Accern’s scale. Accern also gave media stories about the specialty pharmaceutical company an impact score of 46.1541549419916 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Here are some of the media stories that may have effected Accern Sentiment Analysis’s analysis:
- Latest Analysts Reports: Wal-Mart Stores, Inc. (WMT), Antares Pharma, Inc. (ATRS) – AllStockNews (allstocknews.com)
- Indicator Spotter: Watching the Numbers on Shares of Antares Pharma Inc (ATRS) – MTNV (mtnvnews.com)
- Antares Pharma to Present at the Rodman & Renshaw 19th Annual Global Investment Conference – GlobeNewswire (press release) (globenewswire.com)
- Analysts Are Gushing Over Klondex Mines Ltd. (KLDX), Antares Pharma, Inc. (ATRS) – Newburgh Gazette (newburghgazette.com)
A number of equities research analysts recently commented on ATRS shares. HC Wainwright restated a “buy” rating and issued a $5.00 price objective on shares of Antares Pharma in a research report on Friday, June 23rd. Chardan Capital started coverage on shares of Antares Pharma in a research report on Friday, June 23rd. They issued a “buy” rating and a $5.00 price objective for the company. Vetr downgraded shares of Antares Pharma from a “strong-buy” rating to a “buy” rating and set a $3.47 price objective for the company. in a research report on Monday, June 26th. Finally, Piper Jaffray Companies set a $4.00 price objective on shares of Antares Pharma and gave the company a “buy” rating in a research report on Wednesday, July 26th. One investment analyst has rated the stock with a hold rating, three have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Antares Pharma currently has an average rating of “Buy” and a consensus price target of $4.34.
Shares of Antares Pharma (NASDAQ ATRS) remained flat at $3.02 during midday trading on Wednesday. 656,486 shares of the stock were exchanged. The company has a 50-day moving average of $3.08 and a 200-day moving average of $2.88. Antares Pharma has a 12 month low of $1.27 and a 12 month high of $3.37. The firm’s market capitalization is $472.35 million.
Antares Pharma (NASDAQ:ATRS) last issued its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.02) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.01. The company had revenue of $13.42 million during the quarter, compared to analyst estimates of $12.99 million. Antares Pharma had a negative net margin of 34.27% and a negative return on equity of 41.37%. On average, equities research analysts expect that Antares Pharma will post ($0.11) EPS for the current year.
In related news, insider Fred M. Powell purchased 130,000 shares of Antares Pharma stock in a transaction dated Friday, June 9th. The stock was bought at an average cost of $2.79 per share, with a total value of $362,700.00. Following the purchase, the insider now owns 331,434 shares in the company, valued at approximately $924,700.86. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Corporate insiders own 11.60% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/09/06/antares-pharma-atrs-receives-daily-news-sentiment-score-of-0-13.html.
About Antares Pharma
Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops, manufactures and commercializes therapeutic products using its drug delivery systems. Its subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injector system suitable for branded and generic injectable drugs in unit dose containers, reusable needle-free spring-action injector devices, and disposable multi-use pen injectors for use with cartridges.
Receive News & Stock Ratings for Antares Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma Inc. and related stocks with our FREE daily email newsletter.